A ROS-Responsive and Mucoadhesive Thermosensitive Hydrogel Encapsulated with Mizoribine for Synergistic Dry Eye Therapy.

Authors

Danyi Qin, Jiani Li, Panqin Ma, Shinan Wu, Wenying Guan, Yimin Huang, Ke Feng, Mingyan Wei, Zixuan Yang, Shujia Guo, Caihong Huang, Yun-Long Wu, Yi Han, Zuguo Liu

Published in

Advanced science (Weinheim, Baden-Wurttemberg, Germany). Pages e78106. Oct 06, 2026. Epub Oct 06, 2026.

Abstract

Dry eye disease (DED) is a multifactorial disorder characterized by intricate pathogenesis, necessitating a multi-target synergistic intervention strategy. Current anti-inflammatory drugs for DED are limited by low bioavailability, ocular irritation, and inadequate relief. Herein, we propose a multifunctional hydrogel encapsulating Mizoribine, a small-molecule water-soluble immunosuppressant. The formulation undergoes in situ gelation on the ocular surface, forms a mucin-adhered coating, and responds to pathological oxidative stress to enable controlled drug release. In vitro studies demonstrate the formulation effectively mitigates cellular oxidative stress by scavenging ROS and upregulating antioxidant factors. It also protects mitochondrial function, reduces apoptosis, and modulates macrophage polarization. In vivo, topical application of the hydrogel markedly alleviates clinical signs of disease. It also suppresses ocular surface inflammation and reverses conjunctival goblet cell loss. Molecular and cellular analyses indicate the hydrogel exerts its therapeutic effects primarily through antioxidative, anti-inflammatory, and macrophage-modulating mechanisms. Importantly, the formulation exhibits an excellent biosafety profile. Our findings highlight that this multifunctional hydrogel serves as a potent, convenient, and safe nanotherapeutic platform. By integrating ROS-responsive, thermosensitive, and sustained drug-release properties with antioxidant, anti-inflammatory, and immunomodulatory functions, this formulation simultaneously targets multiple pathological pathways, offering a promising avenue for clinical translation in treating chronic ocular surface diseases.

PMID:
42839682
Bibliographic data and abstract were imported from PubMed on 07 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.